Clinical Trials at Methodist Medical Center of Illinois
As of August 2026, 46 paid clinical trials are recruiting at Methodist Medical Center of Illinois, located at 221 NE GLEN OAK AVE, PEORIA, IL 61636, phone (309) 672-5522 in Peoria, Illinois. Active studies at this site cover conditions such as Acute Myeloid Leukemia, Stage IV Lung Cancer AJCC v8 and Anatomic Stage II Breast Cancer AJCC v8. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
46 clinical trials at Methodist Medical Center of Illinois
·Clear filters·Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study
AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Family Communications After Genetic Testing
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Cost Communication and Financial Navigation in Cancer Patients (COSTCOM)
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors
Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases
Common conditions studied in Peoria
- Acute Myeloid Leukemia (6 active studies)
- Stage IV Lung Cancer AJCC v8 (6 active studies)
- Anatomic Stage II Breast Cancer AJCC v8 (5 active studies)
- Head and Neck Squamous Cell Carcinoma (5 active studies)
- Heart Failure (5 active studies)
- Lung Non-Small Cell Carcinoma (5 active studies)
Leading research sponsors in Peoria
- National Cancer Institute (NCI)
- Alliance for Clinical Trials in Oncology
- SWOG Cancer Research Network
- Children's Oncology Group
- NRG Oncology
Frequently asked questions
How many paid clinical trials are currently recruiting in Peoria?
There are approximately 209 recruiting clinical trials in Peoria, Illinois listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Peoria pay participants?
Most recruiting trials in Peoria compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Peoria?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Peoria?
The most common conditions under active study in Peoria include Acute Myeloid Leukemia (6), Stage IV Lung Cancer AJCC v8 (6), Anatomic Stage II Breast Cancer AJCC v8 (5), Head and Neck Squamous Cell Carcinoma (5), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Peoria?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Peoria on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Peoria?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Peoria?
Recruiting research sites in Peoria include Illinois CancerCare-Peoria, Methodist Medical Center of Illinois, OSF Saint Francis Medical Center, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Peoria right now?
The largest active categories in Peoria are Cancer & tumors (123), Cardiovascular (16), Diabetes & metabolic (3). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of Methodist Medical Center of Illinois?
Methodist Medical Center of Illinois is located at 221 NE GLEN OAK AVE, PEORIA, IL 61636. Use the Google Maps link in the intro above to get directions.
How do I contact Methodist Medical Center of Illinois?
You can reach Methodist Medical Center of Illinois by phone at (309) 672-5522. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.